AACR: BMS, clinging to Opdivo's lung cancer share, highlights long-term data

After a hard blow to its hopes in previously untreated lung cancer, Bristol-Myers Squibb is clinging to its share of the second-line market. And it’s hoping new long-term data can help it hang on. Tuesday at the American Association for Cancer Research, the New Jersey drugmaker shared results from a pooled analysis of two phase 3 studies of patients with advanced non-small cell lung cancer who hadn’t received previous treatment. And they showed that at the four-year mark, 14% of all Opdivo-treated patients were still alive, compared with just 5% of those who had received chemo instead. What’s more, 58% of those who had responded to Opdivo at the six-month mark, either partially or completely, were still alive four years later, versus just 12% of chemo patients.